Halozyme Therapeutic (HALO) Stock Price, Quote & News

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 794 8889

Fax: 858 704 8311

Website: halozyme.com

Address:

12390 El Camino Real, San Diego, United States

Sean29md Jun. 16 at 2:02 PM

$HALO Even if CMS discount (2028) applies to Enhanze combo therapeutics (unlikely), according to this article (seeking alpha see below) only Darzelex Faspro will be on the discount list. Darzelx Faspro outside of US and for patients with commercial insurance (not Medicare or Medicaid) will not face this 25% discount. So in terms of the effects on Halozyme earnings, it will be limited to one product (out of 10 approved so far) for CMS patients in the US only and only for a limited time (once biosimilar Darzalex is available, CMS is not allowed to disount per IRB). Based on my calculations the net effect on halo earnings would be around 5-7% for a limited time. Based on PE and PEG ratios, Halo is already trading at 50% discount compared to sector and industry. Huge overreaction! https://seekingalpha.com/article/4794953-halozyme-therapeutics-waters-become-muddled#scroll_comments

0 · Reply

whiteboytrippin Jun. 16 at 1:57 PM

$HALO https://www.nasdaq.com/articles/why-halozyme-therapeutics-halo-top-value-stock-long-term-4

1 · Reply

scalesojustice Jun. 11 at 3:16 PM

$HALO didn't Helen say 'early' June we will hear about MRK case?...it's time, todays rally maybe the prelude to favorable developments

0 · Reply

ballyhooo Jun. 11 at 3:00 PM

$HALO DARZALEX Conversion: The shift to subcutaneous administration reduces treatment time from 3-4 hours to 3-5 minutes. FESGO Reimbursement: Strong adoption in China, driven by reimbursement policies. Vyvgart Hytulo Launch: The prefilled syringe launch allows for a 20-minute subcutaneous injection, enhancing patient convenience. Ocrevus Market Expansion: The subcutaneous version is expanding market reach, with early launches showing 50% of patients new to Ocrevus. Amivantamab Infusion Reaction Reduction: Subcutaneous administration reduces infusion-related reactions from 66% to 13%.

0 · Reply

whiteboytrippin Jun. 10 at 5:03 PM

$HALO Move it, boy.

0 · Reply

Sean29md Jun. 10 at 4:17 PM

$HALO part 2: … For the discerning investors, the answer is no. Anybody spending enough time to read quarterly reports knows that halozyme has given multi-year earnings projections that are based on Enhanze and does not include a dime of revenue from MDASE. So if halo win the MDASE battle with Merck, it would be icing on the cake but if Halo loses, it will not diminish their multi-year guidance by a dime. Regarding CMS, if the decision goes against Halo, at worst, one or two of halo's partnered products may end up on the list of 15 CMS negotiated/discounted drugs. This means a 25% discount only on those 2 meds and only in the US. About half of Enhanze earnings come from outside US and will not be affected. So it would really be a 12.5% discount only. Would any of this justify a PE ration at less than half of market's or peers' PE’s???

0 · Reply

Sean29md Jun. 10 at 4:16 PM

$HALO part 1: Let's for a moment, assume the worst possible scenarios: 1) Merck does not sign a licencing agreement for MDASE 2) Merck succeeds (very unlikely) to invalidate every single claim (about 20 in each patent) in all 13 patents that are in PGR's 3) Merck wins the infringement New Jersey court case (also unlikely) 4) CMS final guidelines does not recognize (unlikely) the significant clinical benefits (reduces side effects, improved efficacy, pt funstion, etc.) of ENHANZE Even if all 4 of these unlikely scenarios take place, should a company with an EPS CAGR of +25% (far better than market and industry averages) and EBITDA margins growing 8% per year from 51% to 73%-75% (also better than market and industry averages) be trading at a PEG ratio of 0.3 and 2025 PE ratio of 10 when average S&P 500 and average biopharma is trading in PE ratios of mid 20's?

0 · Reply

Sean29md Jun. 9 at 6:32 PM

$HALO

0 · Reply

JR603 Jun. 9 at 6:02 PM

$HALO Goldman Sachs Conference - HALO ..... looks like a series of home runs to me!!! https://www.investing.com/news/transcripts/halozyme-at-goldman-sachs-conference-subcutaneous-innovation-drives-growth-93CH-4087223

0 · Reply

Sean29md Jun. 9 at 5:42 PM

$HALO during last earnings call, CEO stated: “Obviously, the PGR we consider to be frankly a little bit of a sideshow. PGRs tend to be filed when companies are concerned that they are infringing and they seek to invalidate the patents. We feel very confident in our ability to prevail in those PGRs. And even if they were to win one or two of the PGRs because there are several in place, we do not believe that will have any impact at all on our infringement at case where we have multiple additional claims that are not subject to the PGR that are the basis of that infringement case. So, two very separate things. The most important one is actually the actual lawsuit that we filed. I’d keep your attention on that one.” https://www.stockinsights.ai/us/0001159036/earnings-transcript/fy25-q1-e012

0 · Reply

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

May 28, 2025, 4:05 PM EDT - 25 days ago

Halozyme to Participate at Upcoming Investor Conferences

May 28, 2025, 8:30 AM EDT - 25 days ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 24, 2025, 8:01 AM EDT - 4 weeks ago

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

AACT AME LNT TW

May 12, 2025, 10:44 AM EDT - 5 weeks ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 6, 2025, 7:15 PM EDT - 6 weeks ago

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 6 weeks ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 5, 2025, 5:15 PM EDT - 6 weeks ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 1, 2025, 9:06 AM EDT - 7 weeks ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

Apr 28, 2025, 8:30 AM EDT - 7 weeks ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 7:30 AM EDT - 7 weeks ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 24, 2025, 8:30 AM EDT - 2 months ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 10, 2025, 6:15 PM EDT - 2 months ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 9, 2025, 8:45 AM EDT - 2 months ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 7, 2025, 9:29 AM EDT - 2 months ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Mar 31, 2025, 8:30 AM EDT - 2 months ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Mar 21, 2025, 7:35 AM EDT - 3 months ago

Halozyme Joins the $1 Billion Club

Feb 26, 2025, 8:30 AM EST - 4 months ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Feb 18, 2025, 7:55 PM EST - 4 months ago

Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 4:01 PM EST - 4 months ago

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

Feb 4, 2025, 8:30 AM EST - 4 months ago

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 3, 2025, 7:30 AM EST - 4 months ago

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Jan 8, 2025, 7:00 AM EST - 5 months ago

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

Jan 6, 2025, 8:30 AM EST - 5 months ago

Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance

Jan 3, 2025, 3:42 PM EST - 6 months ago

Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025

Dec 31, 2024, 2:41 AM EST - 6 months ago

Halozyme: Recent Approvals Alter My Appetite

Dec 30, 2024, 7:00 AM EST - 6 months ago

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Dec 30, 2024, 6:45 AM EST - 6 months ago

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Dec 30, 2024, 6:30 AM EST - 6 months ago

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Nov 27, 2024, 8:30 AM EST - 7 months ago

Halozyme to Present at Upcoming Investor Conferences

Nov 22, 2024, 8:55 AM EST - 7 months ago

Halozyme withdraws $2.1 bln buyout offer for Evotec

EVO

Nov 22, 2024, 8:35 AM EST - 7 months ago

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

EVO

Nov 18, 2024, 4:00 PM EST - 7 months ago

Halozyme CEO: Evotec Is Poised for Growth

EVO

Nov 18, 2024, 7:49 AM EST - 7 months ago

Halozyme says €2 billion takeover of Evotech would create leader in drug discovery

Nov 18, 2024, 7:00 AM EST - 7 months ago

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

EVO

Nov 15, 2024, 12:56 PM EST - 7 months ago

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

EVO

Nov 14, 2024, 4:15 PM EST - 7 months ago

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

EVO

Nov 14, 2024, 4:09 PM EST - 7 months ago

Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports

EVO

Nov 5, 2024, 12:24 PM EST - 8 months ago

Halozyme: Looking For More Growth Following Record Q3 Earnings

Nov 1, 2024, 11:42 AM EDT - 8 months ago

Halozyme Announces Record Earnings, Guidance

Oct 31, 2024, 7:39 PM EDT - 8 months ago

Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:01 PM EDT - 8 months ago

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Oct 24, 2024, 6:30 AM EDT - 8 months ago

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

Oct 23, 2024, 4:30 PM EDT - 8 months ago

Halozyme to Report Third Quarter 2024 Financial and Operating Results

Oct 8, 2024, 4:12 AM EDT - 9 months ago

Wells Fargo Downgrades Halozyme Therapeutics (HALO) Due to Limited Upside

Oct 3, 2024, 8:00 AM EDT - 9 months ago

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

Sep 17, 2024, 8:00 AM EDT - 9 months ago

Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm

Sep 13, 2024, 1:30 PM EDT - 10 months ago

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

Sep 12, 2024, 8:00 PM EDT - 10 months ago

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

Aug 26, 2024, 7:53 AM EDT - 10 months ago

Top 2 Health Care Stocks That May Plunge In August

ONC

Sean29md Jun. 16 at 2:02 PM

0 · Reply

whiteboytrippin Jun. 16 at 1:57 PM

$HALO https://www.nasdaq.com/articles/why-halozyme-therapeutics-halo-top-value-stock-long-term-4

1 · Reply

scalesojustice Jun. 11 at 3:16 PM

$HALO didn't Helen say 'early' June we will hear about MRK case?...it's time, todays rally maybe the prelude to favorable developments

0 · Reply

ballyhooo Jun. 11 at 3:00 PM

0 · Reply

whiteboytrippin Jun. 10 at 5:03 PM

$HALO Move it, boy.

0 · Reply

Sean29md Jun. 10 at 4:17 PM

0 · Reply

Sean29md Jun. 10 at 4:16 PM

0 · Reply

Sean29md Jun. 9 at 6:32 PM

$HALO

0 · Reply

JR603 Jun. 9 at 6:02 PM

0 · Reply

Sean29md Jun. 9 at 5:42 PM

0 · Reply

Sean29md Jun. 9 at 5:28 PM

$HALO Merck clearly knew they were infringing on Halozyme's patents. There is a good chance they (Merck) is now putting up a fight simply to get the best terms in a negotiated MDASE license with halo. They (Merck) were successful in getting the USPO to institute a review on one of Halozyme's patents. Although Merck will ultimately lose some (if not all) of the PGR's, this (the initiation of a review) is a small win for Merck. However, it will likely be all downhill from here for Merck's position. If they don't negotiate a deal with halo now, they will have to do so from a weaker position later, especially if New Jersey court puts a hold on SC Keytruda in an injuction.

0 · Reply

Sean29md Jun. 9 at 12:45 PM

$HALO Let's see what Helen has to say about Merck at Goldman Sachs at 10 am ET.

3 · Reply

NobVega Jun. 5 at 5:44 PM

$HALO Back in $53.52. Patent cases could take a year and if Halo's injunction is approved, MRK will settle.

0 · Reply

Sean29md Jun. 5 at 2:44 PM

$HALO “Btw, Merck is using the PTAB, a mechanism to review wrongly-granted patents, to challenge Halozyme’s patents. Ironically, PhRMA, where Merck is a long-standing member, is lobbying to pass the PREVAIL Act to gut that very mechanism.”

0 · Reply

Sean29md Jun. 5 at 1:30 PM

$HALO Not all these PGR's are the same. For some (eg. 003, 004 and 009), Halozyme did not file a Discretionary Denial motion. But for others (eg. 006 and 017), Halozyme did. Merck needs to win all of these PGR's. Halo needs only one to go its way. https://portal.unifiedpatents.com/ptab/case/PGR2025-00006

0 · Reply

kej32 Jun. 5 at 11:10 AM

$HALO Ok guess after that worthless downgrade we will be stuck in purgatory until the next ER. At least management explained what the real deal was and there is nothing to fear. I’m good with that for now. Easy hold and if they are stupid enough to push this into the $40’s I’m happily pick up more!

0 · Reply

Sean29md Jun. 4 at 4:51 PM

$HALO Halozyme officers and directors, if you do not have enough confidence to personally buy shares at a PEG ratio of 0.3 and 2025 PE ratio of 10, you should step down and let others lead. It is absolutely absurd for a company with EPS CAGR of +25% and EBITDA margins growing 8% per year from 51% to 73%-75% to be trading at such ridiculously low valuations. Do your jobs or step down. https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

1 · Reply

StockHunter75 Jun. 4 at 3:11 PM

$HALO buying more.

0 · Reply

Rogerd9999 Jun. 4 at 2:06 PM

Looks like some very effective Bearish articles have been entered into the fray to influence random readers...if patents are to be eliminated so easily...all heck will break loose in every industry.....yes i hold a bullish long term position in HALO.......$HALO

0 · Reply

Sean29md Jun. 4 at 1:49 PM

$HALO … So for Merck to succeed they have to successfully invalidate every single claim (about 20 in each patent) in every single patent (the 12 they are trying to invalidate through 12 PGR filings), AND win the jury infringement trial (separate matter than PGR’s) for everyone of these 12 patents plus the additional 3 patents that they are not even disputing through PGR’s.

1 · Reply

Sean29md Jun. 4 at 1:49 PM

$HALO $HALO Halozyme One more reason (not mentioned in my previous post) why odds favor Halozyme's sucsess in the patent dispute: Merck would have to prevail in invalidating every single claim in every single PGR. For example in patent #600 (PGR 006) alone, there are about 21 claims in different categories. Claims 1-4, 8-10: Focus on the modified PH20 polypeptide itself, either as a base composition • Claims 11-13: Cover genetic tools (nucleic acid, vector, host cell) for producing the polypeptide. • Claims 14-18: Cover pharmaceutical compositions • Claims 19-20: Describe methods of administering the compositions. • Claim 21: Describes a method of manufacturing the polypeptide. “If any of these remaining claims are upheld as patentable following the trial, the ’600 patent will remain valid with respect to those claims. Conversely, if all remaining claims are found unpatentable, the patent would be invalidated.”

2 · Reply

Tru_Green Jun. 4 at 12:21 PM

$HALO : On May 6th, the Halozyme CEO said she considers the PGR patent petitions 'a little bit of a sideshow':

1 · Reply

Market Cap	6.51B
Revenue (ttm)	1.02B
Net Income (ttm)	444.09M
EPS (ttm)	N/A
PE Ratio	12.46
Forward PE	10.23
Profit Margin	43.74%
Debt to Equity Ratio	3.13

Volume	5,661,700
Avg Vol	2,390,740
Day's Range	N/A - N/A
Shares Out	123.22M
Stochastic %K	6%
Beta	1.19
Analysts	Sell
Price Target	$67.00